Research Results

A comprehensive review of bisphenol A (BPA) research spanning over 20 years—from the landmark 1997 study showing reproductive effects in male mouse offspring at 2 µg/kg/day through the CLARITY-BPA study designed to bridge regulatory and scientific disagreements—found that thousands of animal studies and over 100 epidemiological studies report adverse effects at low doses, with CLARITY-BPA showing effects at 2.5 µg/kg/day, leading independent experts to recommend dropping the lowest observed adverse effect level 20,000-fold from 50,000 to 2.5 µg/kg/day. Despite this overwhelming evidence, the FDA continues to assert BPA is safe by rejecting low-dose data as “not biologically plausible” based on four incorrect assumptions criticized by the Endocrine Society as violating basic principles of endocrinology: that dose responses must be monotonic, thresholds exist below which there are no effects, both sexes must respond similarly, and only traditional toxicological guideline studies are valid. The review highlights a fundamental divide between regulatory approaches and endocrine science, demonstrating that traditional toxicology methods are insufficient for evaluating endocrine-disrupting chemicals like BPA, which can cause non-monotonic dose responses, sex-specific effects, and low-dose effects that challenge conventional assumptions about chemical safety, yet regulatory agencies continue to ignore modern endocrinology principles in favor of outdated toxicological paradigms.